-
Something wrong with this record ?
Use of the biochip microarray system in detection of myocardial injury caused by radiofrequency catheter ablation
R. Pudil, P. Parizek, M. Tichý, L. Haman, L. Horakova, M. Ulrychova, J. Vojáček, V. Palička
Language English Country Germany
Document type Research Support, Non-U.S. Gov't
- MeSH
- Biomarkers analysis blood MeSH
- Adult MeSH
- Myocardial Infarction diagnosis etiology MeSH
- Catheter Ablation adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Microarray Analysis methods MeSH
- Young Adult MeSH
- Prospective Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: In a prospective study, we measured plasma markers of myocardial damage induced by radiofrequency catheter ablation (RFA) with the protein biochip microarray system. METHODS: A total of 32 consecutive patients undergoing RFA for atrioventricular nodal re-entry tachycardia (AVNRT), right atrial flutter (AFL) and atrial fibrillation (AF) were included in the study. Cardiac troponin I (cTnI), creatine kinase isoenzyme MB (CK-MB), heart-type fatty acid binding protein (hFABP) and glycogen phosphorylase BB (GPBB) were measured using biochip array technology at baseline and 24 h after the procedure. RESULTS: Values for all markers increased 24 h after RFA (cTnI: 0.92+/-0.49 microg/L vs. 0.33+/-0.06 microg/L, p<0.001; CK-MB: 3.79+/-2.04 microg/L vs. 1.85+/-0.55 microg/L, p<0.001; hFABP: 2.82+/-0.95 microg/L vs. 2.00+/-0.95 microg/L, p<0.001; GPBB: 9.07+/-5.83 microg/L vs. 4.70+/-2.50 microg/L, p<0.001). The correlations between plasma marker levels and RFA time were cTnI: r=0.63, p<0.01; CK-MB: r=0.75, p<0.01; hFABP: r=0.55, p<0.05, GPBB: r=0.51, p<0.05; the correlation between RFA time and number of RF applications was significant (r=0.81, p<0.001). Patients with RFA due to AF or flutter had elevated cTnI, CK-MB and hFABP levels compared to patients with AVNRT (cTnI: 1.14+/- 0.49 microg/L vs. 0.59+/-0.25 microg/L, p<0.05; CK-MB: 4.46+/- 2.07 microg/L vs. 2.81+/-1.54 mug/L, p<0.05; hFABP: 3.21+/- 0.98 microg/L vs. 2.25+/-0.54 microg/L, p<0.01). CONCLUSIONS: Myocardial injury induced by RFA can be detected by cTnI, CK-MB, hFABP and GPBB. Plasma cTnI, CK-MB and hFABP levels significantly increased in patients with AFL and AF compared to patients with AVNRT. The increase of cTnI, CK-MB and GPBB levels correlates with the total duration of RFA.
- 000
- 01854naa 2200445 a 4500
- 001
- bmc11006227
- 003
- CZ-PrNML
- 005
- 20170223102239.0
- 008
- 110401s2008 gw e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Pudil, Radek $7 xx0040409
- 245 10
- $a Use of the biochip microarray system in detection of myocardial injury caused by radiofrequency catheter ablation / $c R. Pudil, P. Parizek, M. Tichý, L. Haman, L. Horakova, M. Ulrychova, J. Vojáček, V. Palička
- 314 __
- $a First Department of Medicine, Charles University Prague, Faculty of Medicine, Hradec Kralove, Czech Republic. pudilradek@yahoo.com
- 520 9_
- $a BACKGROUND: In a prospective study, we measured plasma markers of myocardial damage induced by radiofrequency catheter ablation (RFA) with the protein biochip microarray system. METHODS: A total of 32 consecutive patients undergoing RFA for atrioventricular nodal re-entry tachycardia (AVNRT), right atrial flutter (AFL) and atrial fibrillation (AF) were included in the study. Cardiac troponin I (cTnI), creatine kinase isoenzyme MB (CK-MB), heart-type fatty acid binding protein (hFABP) and glycogen phosphorylase BB (GPBB) were measured using biochip array technology at baseline and 24 h after the procedure. RESULTS: Values for all markers increased 24 h after RFA (cTnI: 0.92+/-0.49 microg/L vs. 0.33+/-0.06 microg/L, p<0.001; CK-MB: 3.79+/-2.04 microg/L vs. 1.85+/-0.55 microg/L, p<0.001; hFABP: 2.82+/-0.95 microg/L vs. 2.00+/-0.95 microg/L, p<0.001; GPBB: 9.07+/-5.83 microg/L vs. 4.70+/-2.50 microg/L, p<0.001). The correlations between plasma marker levels and RFA time were cTnI: r=0.63, p<0.01; CK-MB: r=0.75, p<0.01; hFABP: r=0.55, p<0.05, GPBB: r=0.51, p<0.05; the correlation between RFA time and number of RF applications was significant (r=0.81, p<0.001). Patients with RFA due to AF or flutter had elevated cTnI, CK-MB and hFABP levels compared to patients with AVNRT (cTnI: 1.14+/- 0.49 microg/L vs. 0.59+/-0.25 microg/L, p<0.05; CK-MB: 4.46+/- 2.07 microg/L vs. 2.81+/-1.54 mug/L, p<0.05; hFABP: 3.21+/- 0.98 microg/L vs. 2.25+/-0.54 microg/L, p<0.01). CONCLUSIONS: Myocardial injury induced by RFA can be detected by cTnI, CK-MB, hFABP and GPBB. Plasma cTnI, CK-MB and hFABP levels significantly increased in patients with AFL and AF compared to patients with AVNRT. The increase of cTnI, CK-MB and GPBB levels correlates with the total duration of RFA.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické markery $x analýza $x krev $7 D015415
- 650 _2
- $a katetrizační ablace $x škodlivé účinky $7 D017115
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikročipová analýza $x metody $7 D046228
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu $x diagnóza $x etiologie $7 D009203
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pařízek, Petr $7 xx0091054
- 700 1_
- $a Tichý, Miloš, $d 1941- $7 xx0112487
- 700 1_
- $a Haman, Luděk $7 xx0063153
- 700 1_
- $a Horáková, Lucie $7 xx0211160
- 700 1_
- $a Vašatová, Martina $7 xx0135924
- 700 1_
- $a Vojáček, Jan, $d 1947- $7 jn20000402578
- 700 1_
- $a Palička, Vladimír, $d 1946- $7 jn99240000830
- 773 0_
- $t Clinical Chemistry & Laboratory Medicine $g Roč. 46, č. 12 (2008), s. 1726-1728 $x 1434-6621 $w MED00010886
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110414100828 $b ABA008
- 991 __
- $a 20170223102435 $b ABA008
- 999 __
- $a ok $b bmc $g 833834 $s 698319
- BAS __
- $a 3
- BMC __
- $a 2008 $b 46 $c 12 $d 1726-1728 $i 1434-6621 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
- LZP __
- $a 2011-1B09/dkjp